DFH partnering with US NCI on new HIV antiretrovirals
This article was originally published in Scrip
Executive Summary
DFH Pharma has teamed with the US National Cancer Institute (NCI) to further the development of next-generation HIV maturation inhibitors, a new class of antiretroviral drugs.